Cidara Therapeutics Files 8-K Report
| Field | Detail |
|---|---|
| Company | Cidara Therapeutics, Inc. |
| Form Type | 8-K |
| Filed Date | Sep 24, 2025 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-k, filing
Related Tickers: CDTX
TL;DR
CDTX filed an 8-K, check the docs for details.
AI Summary
On September 24, 2025, Cidara Therapeutics, Inc. filed an 8-K report. The filing does not contain specific details about events or transactions, but rather serves as a notification of a current report being filed. Further information would be found in the attached documents.
Why It Matters
This filing indicates that Cidara Therapeutics, Inc. has submitted a current report to the SEC, which may contain material updates relevant to investors.
Risk Assessment
Risk Level: low — The filing is a standard procedural 8-K and does not disclose specific negative or positive material events.
Key Players & Entities
- Cidara Therapeutics, Inc. (company) — Registrant
- September 24, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 001-36912 (filing_id) — Commission File Number
- 46-1537286 (ein) — I.R.S. Employer Identification Number
- 6310 Nancy Ridge Drive, Suite 101 (address) — Principal Executive Offices
- San Diego, California 92121 (address) — Principal Executive Offices
- 858-752-6170 (phone) — Principal Executive Offices Telephone Number
FAQ
What is the exact date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is September 24, 2025.
What is the company's full legal name as specified in its charter?
The exact name of the registrant is Cidara Therapeutics, Inc.
In which state was Cidara Therapeutics, Inc. incorporated?
Cidara Therapeutics, Inc. was incorporated in Delaware.
What is the Commission File Number for Cidara Therapeutics, Inc.?
The Commission File Number is 001-36912.
What is the principal executive office address of Cidara Therapeutics, Inc.?
The principal executive offices are located at 6310 Nancy Ridge Drive, Suite 101, San Diego, California 92121.
Filing Stats: 1,025 words · 4 min read · ~3 pages · Grade level 14.3 · Accepted 2025-09-24 07:05:11
Key Financial Figures
- $0.0001 — ich registered Common Stock, Par Value $0.0001 Per Share CDTX The Nasdaq Stock Mar
Filing Documents
- d159459d8k.htm (8-K) — 26KB
- 0001193125-25-214001.txt ( ) — 138KB
- cdtx-20250924.xsd (EX-101.SCH) — 3KB
- cdtx-20250924_lab.xml (EX-101.LAB) — 18KB
- cdtx-20250924_pre.xml (EX-101.PRE) — 11KB
- d159459d8k_htm.xml (XML) — 4KB
Forward-Looking Statements
Forward-Looking Statements This Current Report on Form 8-K contains "forward-looking statements" which include, but are not limited to, all statements that do not relate solely to historical or current facts, such as statements regarding the potential benefits of and future plans for CD388, the expected timing, study design and target enrollment for the planned Phase 3 registrational trial of CD388, the potential to obtain BLA approval based on a single Phase 3 clinical trial and the Company's ability to fully fund the planned Phase 3 development program through completion. These forward-looking statements are subject to the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. The Company's expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks, and changes in circumstances, including but not limited to risks and uncertainties related to unanticipated delays in or negative results from the Company's clinical trials and other risks related to clinical development, delays in action by regulatory authorities, other obstacles associated with the enrollment of patients or other aspects of CD388 or other drug-Fc conjugate development, having to use cash in ways other than as expected and other risks and uncertainties associated with the Company's business in general described in the Company's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2025 filed with Securities and Exchange Commission ("SEC") on August 7, 2025, and in the Company's other filings with the SEC. The Company cautions that the foregoing list of factors is not exclusive and not to place undue reliance upon any forward-looking statements which speak only as of the date made. Except as required by law, the Company does not undertake any obligation to update publicly any forward-looking statements
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Cidara Therapeutics, Inc. Date: September 24, 2025 /s/ Jeffrey Stein, Ph.D. Jeffrey Stein, Ph.D. President and Chief Executive Officer (Principal Executive Officer)